Venn Life Sciences Holdings Share Price London S.E.
Equities
GB00B9275X97
Biotechnology & Medical Research
Sales 2023 | 56.04M 70.38M 5.6B | Sales 2024 * | 62.91M 79.01M 6.29B | Capitalization | 189M 238M 18.91B |
---|---|---|---|---|---|
Net income 2023 | 16M 20.09M 1.6B | Net income 2024 * | 8M 10.05M 800M | EV / Sales 2023 | 2.88 x |
Net cash position 2023 * | 34.79M 43.69M 3.48B | Net cash position 2024 * | 43.8M 55.01M 4.38B | EV / Sales 2024 * | 2.31 x |
P/E ratio 2023 |
10.1
x | P/E ratio 2024 * |
22.3
x | Employees | - |
Yield 2023 * |
1.46% | Yield 2024 * |
0.85% | Free-Float | 60.77% |
Latest transcript on Venn Life Sciences Holdings
Managers | Title | Age | Since |
---|---|---|---|
Yamin Khan
CEO | Chief Executive Officer | 55 | 12/10/21 |
Ian O'Connell
FOU | Founder | 37 | 31/01/11 |
Cathal Friel
FOU | Founder | 59 | 31/01/11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 07/06/22 | |
Cathal Friel
FOU | Founder | 59 | 31/01/11 |
Brendan Buckley
FOU | Founder | 73 | 30/11/18 |
1st Jan change | Capi. | |
---|---|---|
+26.49% | 44.96B | |
-0.79% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.52% | 26.08B | |
-21.21% | 19.03B | |
+6.03% | 12.75B | |
+28.51% | 12.06B | |
-3.37% | 11.75B |